Composition for inducing auto-ubiquitination of DDB1 protein comprising a denedylation inhibitor as an active ingredient

A denedylation inhibitor induces auto-ubiquitination of DDB1 protein to enhance cancer drug sensitivity and block DNA repair, effectively inhibiting cancer cell proliferation and promoting cell death.

KR103046687B1Active Publication Date: 2026-11-11CHUNGBUK NAT UNIV IND ACADEMIC COOPERATION FOUND
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
KR1020240095527
Authority / Receiving Office
KR · KR
Patent Type
Patents
Current Assignee / Owner
Filing Date
2024-07-19
Publication Date
2026-11-11
Estimated Expiration
2044-07-19

AI Technical Summary

Technical Problem

Existing anticancer drugs targeting the Cullin-RING E3 ubiquitin ligase (CRL) complex face challenges in effectively inducing auto-ubiquitination of the DDB1 protein, leading to dysregulated DNA damage repair and reduced drug sensitivity in cancer cells.

Method used

A composition comprising a denedylation inhibitor, such as CSN5i-3, is used to induce auto-ubiquitination of the DDB1 protein, combined with DNA damaging agents to block DNA repair and enhance cancer drug sensitivity.

Benefits of technology

The denedylation inhibitor effectively induces DDB1 protein degradation via auto-ubiquitination, enhancing the sensitivity of cancer cells to DNA-damaging agents and inhibiting cancer cell proliferation and repair, thereby promoting cancer cell death.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 112024078607895-PAT00002_ABST
    Figure 112024078607895-PAT00002_ABST
Patent Text Reader

Abstract

The present invention relates to a composition for inducing self-ubiquitination of DDB1 protein comprising a denedylation inhibitor as an active ingredient; a composition for enhancing sensitivity to anticancer drugs and a composition for adjuvant use of the same; and a pharmaceutical combination formulation for cancer treatment comprising a composition for inducing self-ubiquitination of DDB1 protein and a DNA damaging agent. Since the denedylation inhibitor of the present invention can induce self-ubiquitination of DDB1 protein, when applied to cancer cells, it can effectively block the repair process following DNA damage; therefore, when an anticancer drug capable of causing DNA damage is used in combination with the denedylation inhibitor, it is possible to effectively induce cancer cell death along with inhibition of cancer cell proliferation.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] The present invention relates to a composition for inducing self-ubiquitination of DDB1 protein comprising a denedylation inhibitor as an active ingredient; a composition for enhancing anticancer drug sensitivity and a composition for adjuvant anticancer drug use utilizing the same; and a pharmaceutical combination formulation for cancer treatment comprising a composition for inducing self-ubiquitination of DDB1 protein and a DNA damaging agent. Background Technology

[0002] The Cullin-RING E3 ubiquitin ligase (CRL) complex, which regulates the ubiquitination of approximately 20% of intracellular proteins involved in cell cycle regulation, DNA replication, and genetic material stability, is composed of four constituent proteins. Centered around Cullin (CUL), which acts as the scaffold, the complex is formed by a Receptor protein that recognizes substrates at the N-terminus and an Adaptor protein that connects Cullin to the Receptor protein, while the E2 enzyme RBX protein forms the CRL complex at the C-terminus. Cullin undergoes nedylation when the NEDD8 protein binds to the C-terminal lysine residue; this activates the CRL complex, which recognizes substrates and degrades them via the Ubiquitin Proteasome System (UPS). Various Adaptor and Receptor proteins exist depending on the eight types of Cullin, which is why the CRL complex functions in the degradation of diverse intracellular proteins.

[0003] DDB1 is an adapter protein that links Cullin4 (CUL4) and DCAF (DDB1-CUL4-Associated Factor) proteins within the CRL4 (Cullin-RING Ligase 4) complex. DDB1 is known to constitute the CRL4 complex and play a crucial role in DNA damage repair within cells, as well as in the degradation of proteins involved in cell cycle regulation. DDB1 binds with DDB2 to form the UV-DDB damage recognition complex, recognizes the site of damage, and functions in DNA damage repair by recruiting proteins necessary for Global Genomic Nucleotide Excision Repair (GG-NER).

[0004] In most cancer cells, the CRL complex exhibits excessive activity or dysregulation. For this reason, various anticancer drugs targeting the nedylation of the CRL complex have been developed.

[0005] Against this background, while studying the regulation of CRL complex dynamics using the denedylation inhibitor CSN5i-3, the inventors confirmed that DDB1, an adapter protein of CRL4, was reduced at the protein level and were the first to identify that this protein reduction was due to degradation by auto-ubiquitination. Based on the above results, the present invention was completed by hypothesizing that cancer cell death can be effectively induced by administering an anticancer drug capable of causing DNA damage after inducing auto-ubiquitination of the DDB1 protein through a denedylation inhibitor to block the repair process following DNA damage. Prior art literature

[0006] US Patent Publication US 2021 / 0293788 A1 The problem to be solved

[0007] Therefore, the objective of the present invention is to provide a composition capable of effectively inducing auto-ubiquitination of the DDB1 protein.

[0008] Another objective of the present invention is to provide a composition for enhancing anticancer drug sensitivity using a composition capable of effectively inducing auto-ubiquitination of the DDB1 protein.

[0009] Another objective of the present invention is to provide an anticancer adjuvant composition using a composition capable of effectively inducing auto-ubiquitination of the DDB1 protein.

[0010] Another objective of the present invention is to provide a pharmaceutical combination formulation for the prevention or treatment of cancer comprising a composition capable of effectively inducing auto-ubiquitination of the DDB1 protein and a DNA damaging agent. means of solving the problem

[0011] In order to achieve the objectives of the present invention as described above,

[0012] The present invention provides a composition for inducing auto-ubiquitination of DDB1 protein, comprising a denedylation inhibitor as an active ingredient.

[0013] In one embodiment of the present invention, the denedylation inhibitor may be CSN5i-3.

[0014] In addition, the present invention relates to a composition for enhancing anticancer drug sensitivity, comprising as an active ingredient a composition for inducing auto-ubiquitination of the DDB1 protein.

[0015] In one embodiment of the present invention, the anticancer agent may be a DNA damaging agent.

[0016] In one embodiment of the present invention, the DNA damaging agent may be selected from the group consisting of ionizing radiation, radiogenic neocarzinostatin, platinating agents, topo I inhibitors, topo II inhibitors, anmetatars, alkylating agents, and antibiotics.

[0017] In addition, the present invention provides an anticancer adjuvant composition comprising, as an active ingredient, a composition for inducing auto-ubiquitination of the DDB1 protein.

[0018] In one embodiment of the present invention, the anticancer agent may be a DNA damaging agent.

[0019] In addition, the present invention provides a pharmaceutical combination formulation for the prevention or treatment of cancer, comprising a composition for inducing auto-ubiquitination of the DDB1 protein and a DNA damaging agent as an active ingredient.

[0020] In one embodiment of the present invention, the DNA damaging agent may be selected from the group consisting of ionizing radiation, radiogenic neocarzinostatin, platinating agents, topo I inhibitors, topo II inhibitors, anmetatars, alkylating agents, and antibiotics.

[0021] In one embodiment of the present invention, the composition for inducing self-ubiquitination of the DDB1 protein may be administered simultaneously, separately, or sequentially with a DNA damaging agent.

[0022] In one embodiment of the present invention, the cancer may be one or more cancers selected from the group consisting of lung cancer, stomach cancer, colorectal cancer, liver cancer, bone cancer, pancreatic cancer, skin cancer, head or neck cancer, skin or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, pro-anal cancer, colon cancer, breast cancer, fallopian tube carcinoma, endometrial carcinoma, cervical carcinoma, vaginal carcinoma, vulvar carcinoma, Hodgkin's disease, esophageal cancer, small intestine cancer, endocrine gland cancer, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, prostate cancer, chronic or acute leukemia, lymphocytic lymphoma, bladder cancer, kidney or ureteral cancer, renal cell carcinoma, renopelvic carcinoma, CNS tumor, primary CNS lymphoma, spinal cord tumor, brainstem glioma, pituitary adenoma and osteosarcoma. Effects of the invention

[0023] The denedylation inhibitor of the present invention can induce self-ubiquitination of the DDB1 protein. When applied to cancer cells, it can effectively block the repair process following DNA damage. Therefore, when the denedylation inhibitor is used in combination with an anticancer agent capable of causing DNA damage, it can effectively induce cancer cell death along with inhibition of cancer cell proliferation. Brief explanation of the drawing

[0024] Figure 1a shows the results of Western blot analysis of the reduction in DDB1 protein after treating small cell lung cancer cell line DMS114 with the denedylation inhibitor CSN5i-3 in a concentration-dependent and time-dependent manner. Figure 1b shows the results of confirming the mRNA levels of DDB1 in cells by qRT-PCR after treating small cell lung cancer cell line DMS114 with the denedylation inhibitor CSN5i-3 (1 μM, 24 Hr). Figure 1c shows the results of Western blot analysis of changes in DDB1 protein after treating small cell lung cancer cell line DMS114 with the denedylation inhibitor CSN5i-3 (1 μM, 24 Hr) and the protein synthesis inhibitor cycloheximide (CHX: 10 μM, 24 Hr). Figure 1d shows the results of Western blot analysis of changes in DDB1 protein after treating small cell lung cancer cell line DMS114 with the denedylation inhibitor CSN5i-3 (1 μM, 24 Hr) and the proteasome inhibitor MG132 (10 μM, 24 Hr). Figure 1e shows the results of Western blot analysis of changes in DDB1 protein after treating small cell lung cancer cell line DMS114 with the denedylation inhibitor CSN5i-3 (1 μM, 24 Hr) and the autophagy inhibitor chloroquine (CQ: 10 μM, 24 Hr). Figure 2a shows the results of Western blot analysis of changes in DDB1 protein after treating small cell lung cancer cell line DMS114 with the denedylation inhibitor CSN5i-3 (1 μM, 24 Hr) and the denedylation inhibitor pevonedistat (1 μM, 24 Hr). Figure 2b shows the results of Western blot analysis of changes in DDB1 protein after treating small cell lung cancer cell line DMS114 with the denedylation inhibitor CSN5i-3 (1 μM, 24 Hr) and siRNA (siCUL4A, siCUL4B). Figure 2c shows the upper panel, which is the result of quantifying the change in DDB1 protein shown in the Western blot of Figure 2b using a heatmap, and the lower graph, which is the result of quantifying the decrease in CUL4A and CUL4B proteins shown in the Western blot of Figure 2b. Figure 3 shows the intracellular locations where self-ubiquitination of the DDB1 protein occurs in the small cell lung cancer cell line DMS114 induced by the denedylation inhibitor CSN5i-3. 3A shows the results of Western blot analysis using Subcellular Fractionation to identify the intracellular locations where the DDB1 protein undergoes self-ubiquitination after treating the small cell lung cancer cell line DMS114 with the denedylation inhibitor CSN5i-3 (1 μM, 24 Hr). The upper panel of 3B quantifies the degradation of the DDB1 protein shown in the Western blot of 3A using a heatmap, and the lower panel quantifies the proportion of the DDB1 protein by intracellular location shown in the Western blot of 3A. Figure 4 confirms the synergistic effect between the denedylation inhibitor CSN5i-3 and the DNA damage drug etoposide in small cell lung cancer cell line DMS114. 4A compares growth inhibition via a colony formation assay after treating small cell lung cancer cell line DMS114 with the denedylation inhibitor CSN5i-3 (30 nM) and the DNA damage drug Etoposide (30 nM) alone or together (co-treatment total 60 nM), and 4B is a graph quantifying the cell growth inhibition shown through the colony formation assay. Specific details for implementing the invention

[0025] In one embodiment, the present invention relates to a composition for inducing auto-ubiquitination of DDB1 protein, comprising a denedylation inhibitor as an active ingredient.

[0026] In the present invention, the DDB1 protein is an adapter protein that connects the Cullin4 (CUL4) protein and the DCAF (DDB1-CUL4-Associated Factor) protein in the CRL4 (Cullin-RING Ligase 4) complex.

[0027] The DDB1 protein of the present invention may be composed of an amino acid sequence having sequence homology of at least 70%, preferably at least 80%, more preferably at least 90%, and even more preferably at least 95% with respect to SEQ ID NO. 1, and exhibiting a function substantially equivalent to the amino acid sequence represented by SEQ ID NO. 1.

[0028] Accordingly, the range of the DDB1 protein according to the present invention includes a protein having an amino acid sequence represented by SEQ ID NO. 1 and a functional equivalent of said protein. "Functional equivalent" refers to a protein that exhibits substantially the same physiological activity as the protein represented by SEQ ID NO. 1, having at least 70%, preferably 80%, more preferably 90%, and even more preferably 95% sequence homology with the amino acid sequence represented by SEQ ID NO. 1 as a result of the addition, substitution, or deletion of amino acids.

[0029] In the present invention, “neddylation” refers to the action of NEDD8 binding to a target protein to induce a modification of the protein, and “deneddylation” refers to the process of NEDD8 detaching from the target protein. NEDD8 (Neural precursor cell-Expressed Developmental Downregulation 8) is a type of ubiquitin-like protein, a small protein of 11 kDa, and through the process of covalently bonding to lysine residues of other proteins, the function of the protein to which NEDD8 is bound is altered.

[0030] In the present invention, the “denedylation inhibitor” is a substance that inhibits the process of NEDD8 detaching from a target protein.

[0031] In the present invention, “ubiquitination” is a post-translational modification (PTM) of a protein in which a small 8.5 kDa ubiquitin protein composed of 76 amino acids is linked to a substrate protein, and is also referred to as ubiquitylation. Depending on ubiquitination, the substrate protein may be degraded by the proteasome, its activity may be affected, its location within the cell may change, and protein interactions may be promoted or inhibited. Ubiquitination occurs through three processes: activation, conjugation, and ligation. Each process is carried out by an enzyme such as ubiquitin activating enzyme (E1), ubiquitin conjugating enzyme (E2), and E3 ubiquitin ligase.

[0032] In the present invention, “auto-ubiquitination” means self-ubiquitination.

[0033] In the present invention, it was first discovered that a denedylation inhibitor induces self-ubiquitination of DDB1, an adapter protein of the CRL4 complex.

[0034] Accordingly, the composition of the present invention is characterized by comprising a denedylation inhibitor as an active ingredient as a composition for inducing auto-ubiquitination of DDB1 protein.

[0035] In one embodiment of the present invention, the denedylation inhibitor may be a CSN (COP9 signalosome) inhibitor, for example, a CSN5 inhibitor such as CSN5i-1, CSN5i-2, CSN5i-2e, or CSN5i-3, but is not specifically limited to that type.

[0036] In the present invention, “CSN5i-3” is a compound having the structure of the following chemical formula 1, C 28 H 29 It has the molecular formula F2N5O2.

[0037] <Chemical Formula 1>

[0038]

[0039] In another aspect, the present invention relates to a composition for enhancing anticancer drug sensitivity comprising a composition for inducing auto-ubiquitination of the DDB1 protein as an active ingredient.

[0040] In another aspect, the present invention relates to an anticancer adjuvant composition comprising a composition for inducing auto-ubiquitination of the DDB1 protein as an active ingredient.

[0041] The denedylation inhibitor of the present invention can induce self-ubiquitination of the DDB1 protein; therefore, when a composition containing this as an active ingredient is applied to cancer cells, the repair action following DNA damage can be effectively blocked, and thus it can be usefully employed to enhance the sensitivity (the degree to which cancer cells respond to anticancer drugs) or as an adjuvant for anticancer drugs.

[0042] In one embodiment of the present invention, the anticancer agent may be a DNA damaging agent.

[0043] The above DNA damaging agent may be selected from the group consisting of ionizing radiation, radiogenic neocarzinostatin, platinating agents, topo I inhibitors, topo II inhibitors, anmetatars, alkylating agents, and antibiotics.

[0044] Examples of the above platinum compounding agents include cisplatin, oxaliplatin, carboplatin, nedaplatin, lobaplatin, trilatine tetranitrate, picoplatin, satraplatin, prolindac, and aroplatin.

[0045] Examples of the above-mentioned topo I inhibitors include camptothecin, topotecan, irinotecan / SN38, rubitecan, and belotecan.

[0046] Examples of the above-mentioned topo II inhibitors include etoposide, daunorubicin, doxorubicin, aclarubicin, epirubicin, idarubicin, amrubicin, pirarubicin, valubicin, zorubicin, and tenifoside.

[0047] Examples of the above anmetatadine include aminopterin, methotrexate, pemetrexed,

[0008] raltitrexed, pentostatin, cladribine, cloparabine, fludarabine, thioguanine, mercaptopurine, fluorouracil, capecitabine, tegafur, camofur, fluoxuridine, cytarabine, gemcitabine, 6-mercaptopurine, 5-fluorouracil, azacitidine, and hydroxyurea.

[0048] Examples of the above alkylating agents include mechlorethamine, cyclophosphamide, ifosfamide, trophosphamide, chlorambucil, melphalan, prednimustine, bendamustine, uramustine, estramustine, carmustine, lomustine, semustine, potemustine, nimustine, ranimustine, streptozosin, busulfan, mannosulfan, threosulfan, carboquone, thiotepa, triaziquone, triethylenemelamine, procarbazine, dacarbazine, temozolomide, altretamine, mitobronitol, actinomycin, bleomycin, mitomycin, nitrogen mustard, nitrosourea, triagen, alkyl sulfonate, procarbazine, aziridine, and plicamycin.

[0049] Examples of the above antibiotics include hydroxyurea, anthracycline, anthracendione, and Streptomyces class.

[0050] In another aspect, the present invention relates to a composition for inducing auto-ubiquitination of DDB1 protein and a pharmaceutical combination formulation for the prevention or treatment of cancer comprising a DNA damaging agent as an active ingredient.

[0051] The pharmaceutical combination formulation of the present invention may contain a composition for inducing auto-ubiquitination of DDB1 protein and a DNA damaging agent as active ingredients, and may be any form of drug. For example, a combination formulation containing two active ingredients may be formed, or each may be formed as a single formulation. Here, a combination formulation refers to a formulation in which two or more active ingredients are combined, and a single formulation refers to a formulation containing a single active ingredient; in this case, the active ingredients may be manufactured in different formulations according to their respective pharmacological and pharmacokinetic characteristics and then combined. In the present invention, when the two active ingredients are single formulations, the therapeutic agent refers to a drug that utilizes a combination of single formulations that can each be used individually. When the two active ingredients are single formulations, they may be in the form of a kit containing both ingredients at once.

[0052] The pharmaceutical combination formulations of the present invention may be formulated by known methods, either alone or together with suitable pharmaceutically acceptable carriers or excipients as described below. Specific examples of such formulations include oral preparations such as soft capsules, hard capsules, tablets, and syrups, or injectable preparations.

[0053] Pharmaceutically acceptable carriers include any of the standard pharmaceutical carriers used in known formulations such as sterile solutions, tablets, coated tablets, and capsules. Typically, these carriers include excipients such as polyvinylpyrrolidone, dextrin, starch, milk, sugar, certain types of clay, gelatin, stearic acid, talc, vegetable oils (e.g., edible oil, cottonseed oil, coconut oil, almond oil, peanut oil), oil phase esters of neutral fatty acid glycerides, mineral oil, petroleum jelly, animal fat, cellulose derivatives (e.g., crystalline cellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose), or other known excipients. These carriers may also include antioxidants, wetting agents, viscosity stabilizers, flavoring agents, color additives, and other ingredients. Pharmaceutical combination formulations containing such a carrier can be formulated by a known method.

[0054] The pharmaceutical combination formulation of the present invention may be administered daily or intermittently, and the number of administrations per day may be divided into one or several. When the two active ingredients are each monotherapys, the number of administrations may be the same or different. Additionally, the pharmaceutical combination formulation of the present invention may be administered at a pharmaceutically effective amount for cancer treatment. Typical dosage levels; and the ratio of the composition for inducing auto-ubiquitination of DDB1 protein and the DNA damaging agent can be optimized using standard clinical techniques.

[0055] Examples of types of cancer for which the pharmaceutical combination formulation of the present invention can exhibit a therapeutic effect include, but are not limited to, lung cancer, gastric cancer, colorectal cancer, liver cancer, bone cancer, pancreatic cancer, skin cancer, head or neck cancer, skin or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, pro-anal cancer, colon cancer, breast cancer, fallopian tube carcinoma, endometrial carcinoma, cervical carcinoma, vaginal carcinoma, vulvar carcinoma, Hodgkin's disease, esophageal cancer, small intestine cancer, endocrine gland cancer, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, prostate cancer, chronic or acute leukemia, lymphocytic lymphoma, bladder cancer, kidney or ureteral cancer, renal cell carcinoma, renopelvic carcinoma, CNS tumor, primary CNS lymphoma, spinal cord tumor, brainstem glioma, pituitary adenoma, and osteosarcoma.

[0056] In another aspect, the present invention relates to the use of a pharmaceutical combination formulation comprising a composition for inducing the self-ubiquitination of a DDB1 protein and a DNA damaging agent as an active ingredient for the manufacture of a drug for cancer treatment. The pharmaceutical combination formulation of the present invention, comprising a composition for inducing the self-ubiquitination of a DDB1 protein and a DNA damaging agent as an active ingredient, can be used for the manufacture of a drug for cancer treatment.

[0057] In another aspect, the present invention relates to a method for treating cancer comprising administering a therapeutically effective amount of the pharmaceutical combination formulation of the present invention to a mammal.

[0058] As used herein, the term "mammal" refers to a mammal that is the subject of treatment, observation, or experiment, preferably a human.

[0059] As used herein, the term "therapeutic effective dose" refers to the amount of an active ingredient that exhibits alleviating, inhibiting, improving, and / or curative effects on the disease (cancer) to be treated. The dosage of the composition for inducing auto-ubiquitination of DDB1 protein and the DNA damaging agent according to the present invention may vary depending on various factors, and the route of administration may also vary, such as oral or parenteral, depending on various factors including the patient's age, duration of administration, body weight, severity of the disease, patient consciousness, and the type of concomitant drugs. Furthermore, it is possible to administer each simultaneously, separately, or sequentially.

[0061] The present invention will be explained in more detail below through examples. These examples are intended to explain the invention more specifically, and the scope of the invention is not limited to these examples.

[0063] <Example>

[0065] 1. Materials and Methods

[0067] cell culture

[0068] The human small cell lung cancer cell line DMS114 was obtained from the American Type Culture Collection (www.Atcc.org) and tested for Mycoplasma (Lonza LT07-418). The DMS114 cell line was subcultured every 3–5 days in Roswell Park Memorial Institute medium (Invitrogen; 11875-119) with the addition of heat-inactivated 10% fetal bovine serum (FBS; Invitrogen; 10082-147) and 1× penicillin / streptomycin (Invitrogen; 10378-016). The DMS114 cell line was cultured at 37°C in a 5% CO2 incubator.

[0070] drugs

[0071] The NAE1 inhibitor pevonedistat and the CSN5 inhibitor CSN5i-3 were purchased from Sigma-Aldrich (Cat. 505477) and MedChemExpress (Cat. HY112134), respectively, while the proteasome inhibitor MG132 and the autophagy inhibitor chloroquine (CQ) were purchased from Millipore (Cat. 11134515001) and Sigma (Cat. C6628), respectively. Each drug was administered to the cell lines according to the concentrations and times indicated in the diagram.

[0073] Western blot

[0074] For Western blot, primary antibodies were used for each protein: anti-CUL4A (Abcam, ab92554, 1:10,000), anti-CUL4B (Abcam, ab67035, 1:1000), anti-α-tubulin (Millipore, T9026, 1:10,000), anti-histone H3 (Millipore, 07-690, 1:25,000), anti-LMNB2 (Cell Signaling, 13823, 1:2000), anti-DDB1 (Cell Signaling; 5428; 1:1000), and anti-LC3B (Novus, NB100-2220, 1:10,000). Subsequently, secondary antibodies Horseradish peroxidase (HRP)-linked anti-mouse IgG (Cell signaling; 7076) and HRP-linked anti-rabbit IgG (Cell signaling; 7074) were used. All antibodies were used according to the manufacturer's manual, and all data were quantitatively analyzed using GraphPad Prism version 9 (GraphPad Software).

[0076] Quantitative Real Time PCR (qRT-PCR)

[0077] Total RNA was extracted from the DMS114 cell line Control group and CSN5i-3 group (1 μM, 24 Hr) using the RNeasy R Mini Kit (Qiagen, 74104). cDNA was synthesized from the extracted RNA using PrimeScriptRT Master Mix (Takara, RR036A). qRT-PCR was performed using the synthesized cDNA and SYBR Green PCR Master Mix (Invitrogen, 4309155). The expression level of the DDB1 transcript was standardized using GAPDH as a qRT-PCR control. GAPDH primers (Forward: 5'-GAG TCA ACG GAT TTG GTC GT-3', Reverse: 5'-TTG ATT TTG GAG GGA TCT CG-3), DDB1 primers (Forward: 5'-CAT TCC TCG CTC CAT CCT GAT G-3', Reverse: 5'-CCT TCT TAC GGT CGC TCA ACA G-3').

[0079] siRNA

[0080] 5× siRNA Buffer (Cat. B-002000-UB-100), Accell siRNA Delivery Media (Cat. B-005000-500), Accell Human CUL4A (8451) siRNA-SMARTpool (Cat. E-012610-00-0005), and Accell Human CUL4B (8450) siRNA-SMARTpool (Cat. E-017965-00-0005) were purchased from Dharmacon. Each siRNA was diluted using 5× siRNA Buffer, and each siRNA (10 μM, 72 Hr) was added to DMS114 cell lines and cultured in Accell siRNA Delivery Media at 37°C in a 5% CO2 incubator. siCUL4A: A-012610-13, A-012610-14, A-012610-15 and A-012610-16 target the sequences GCA UGU GGA UUC AAA GUU A, UGC AGG UGU AUA AAG AUU C, CUU AUA AGU UCG UUG UGU C and GUC AUA AUC UUC UAG UUU C, respectively. siCUL4B: A-017965-13, A-017965-14, A-017965-15 and A-017965-16 target the sequences CUA UUG UAA UUA AUC CUG A, GCA GAA UUU AAA GAG GGU A, CUU UUA GAU AGA GUU GGU C and GCA UGU UAU UUA GUA UGA U, respectively.

[0082] Subcellular Fractionation

[0083] DMS114 cell line Control group and CSN5i-3 group (1 μM, 24 Hr) were sampled using the cytosol, membrane, soluble nucleus, and chromatin fraction buffer of the Subcellular protein fractionation kit (Thermo Fisher Scientific; 78840) according to the manufacturer's manual. During the sampling process, phenylmethylsulfonyl fluoride, a protease inhibitor cocktail, and a phosphatase inhibitor cocktail were used.

[0085] Colony formation assay

[0086] 5×10⁴ DMS114 cell lines in each well of a 24-well plate 6 After dispensing, the cells were divided into a CSN5i-3 treatment group, an etoposide treatment group, and a group treated with both CSN5i-3 and etoposide, and drugs were administered according to each group. The drugs were administered at a dose of 30 nM to the cell lines in each group (for co-treatment, a total of 60 nM was administered, consisting of 30 nM of CSN5i-3 and 30 nM of etoposide), and the cell lines were stained with crystal violet.

[0088] 2. Results

[0090] Changes in DDB1 protein levels, mRNA expression, protein production, and protein stability following treatment with denedylation inhibitors

[0091] [Changes in DDB1 Protein Levels]

[0092] To determine whether the auto-ubiquitination of receptor proteins within the CRL complex observed upon treatment with denedylation inhibitors also occurs in adapter proteins within the CRL complex, changes in the CRL4 adapter protein DDB1 were examined by performing Western blots after treating DMS114 (small cell lung cancer) cell lines with denedylation inhibitors in a concentration-dependent and time-dependent manner.

[0093] As a result, as shown in Figure 1a, it was confirmed that the protein level of DDB1 decreased as the treatment concentration of the denedylation inhibitor increased and the treatment time increased. This indicates that the protein level of DDB1 was reduced by the denedylation inhibitor CSN5i-3.

[0094] In this invention, studies were conducted for each purpose to determine whether the decrease in DDB1 protein levels is caused by changes in mRNA levels, changes in protein production, or changes in protein stability.

[0095] [Changes in mRNA expression levels]

[0096] First, to confirm changes in the mRNA of the DDB1 protein, qRT-PCR (Quantitative Real Time-Polymerase Chain Reaction) was performed after treating the DMS114 (small cell lung cancer) cell line with a denedylation inhibitor.

[0097] As a result, as shown in Figure 1b, it was confirmed that there was no change in the mRNA level of DDB1 when treated with a denedylation inhibitor.

[0098] [Changes in protein production]

[0099] Next, to confirm changes in DDB1 protein production, DMS114 (small cell lung cancer) cell lines were treated with a denedylation inhibitor (CSN5i-3) and a protein production inhibitor, cycloheximide, and analyzed by Western blot.

[0100] As a result, as shown in Figure 1c, it was confirmed that the protein level of DDB1 decreased further when treated with a denedylation inhibitor. Since this implies that the stability of the DDB1 protein has decreased, the change in the stability of DDB1 upon treatment with a denedylation inhibitor was next examined.

[0101] [Changes in Protein Stability]

[0102] Western blot was performed on DMS114 (small cell lung cancer) cell lines treated with a denedylation inhibitor, a UPS (Ubiquitin Proteasome System) inhibitor, and an autophagy inhibitor.

[0103] As a result, it was confirmed that the protein level of DDB1 was restored when the denedylation inhibitor and the UPS inhibitor MG132 were treated together (see Fig. 1d), and that the protein level of DDB1 was not restored when the denedylation inhibitor and the autophagy inhibitor CQ (Chloroquine) were treated together (see Fig. 1e).

[0104] Based on the above results, it was found that the decrease in DDB1 protein observed upon treatment with a denedylation inhibitor is due to protein degradation via USP.

[0106] Denedylation inhibitor-induced auto-ubiquitination of DDB1 protein

[0107] In this experiment, to determine whether the degradation of DDB1 protein upon treatment with a denedylation inhibitor is a phenomenon caused by the CRL complex, Western blot was performed after treating DMS114 (small cell lung cancer) cell lines with pevonedistat (MLN4924), a denedylation inhibitor that inactivates Cullin, and a denedylation inhibitor (CSN5i-3).

[0108] As a result, as shown in Figure 2a, it was found that the protein level of DDB1 was restored when treated with a nedylation inhibitor that inactivates Cullin. This implies that the degradation of DDB1 protein upon treatment with a denedylation inhibitor is caused by Cullin.

[0109] However, since fevonedistat (MLN4924) is a nedylation inhibitor that inhibits the activity of other nedylation proteins as well, to determine whether the decrease in DDB1 protein observed upon treatment with a denedylation inhibitor is a phenomenon caused by self-ubiquitination by CRL4, DMS114 (small cell lung cancer) cell lines were treated with CUL4 siRNA and a denedylation inhibitor together and confirmed using Western blot.

[0110] As a result, as shown in Figures 2b and 2c, it was confirmed that the degradation of DDB1 protein upon treatment with a denedylation inhibitor was restored when the expression of CUL4 was reduced. Through this, it was found that the reduction of DDB1 protein induced by treatment with a denedylation inhibitor is due to degradation caused by self-ubiquitination by CRL4.

[0112] Confirmation of the intracellular localization of the DDB1 protein

[0113] In this experiment, to determine the intracellular location of self-ubiquitination of the DDB1 protein induced by a denedylation inhibitor, DMS114 (small cell lung cancer) cell lines were treated with a denedylation inhibitor (CSN5i-3), and the proteins were separated according to their intracellular location using subcellular fractionation and then verified using Western blot.

[0114] As a result, as shown in Figure 3, a decrease in DDB1 protein was confirmed at all locations within the cell, and through heat map quantification, it was confirmed that the rate of decrease in DDB1 protein in the nucleus was greater than the rate of decrease in DDB1 protein in the cytoplasm.

[0116] Synergistic effect of cancer cell growth inhibition by combined treatment of denedylation inhibitors and DNA damage drugs

[0117] In this experiment, we confirmed through a colony formation assay whether a synergistic effect actually occurs in inhibiting cancer cell growth when the DDB1 protein, which is important for DNA damage repair, is reduced using a denedylation inhibitor and a DNA damage-repairing drug is administered simultaneously.

[0118] As a result, as shown in Figure 4, it was confirmed that the group treated simultaneously with the denedylation inhibitor CSN5i-3 and the DNA damage drug etoposide in small cell lung cancer cell line DMS114 showed a significantly superior effect in inhibiting cancer cell growth compared to the single-drug treatment group.

[0120] The DDB1 protein is a very important protein responsible for repairing DNA damage within cells. Based on previous results, we hypothesized that inducing self-ubiquitination of the DDB1 protein in cancer cells using a dnedylation inhibitor to block the repair process following DNA damage, followed by the administration of an anticancer drug capable of causing DNA damage, would result in the inhibition of cancer cell growth and death. Consequently, we treated DMS114 (small cell lung cancer) cell lines with both a dnedylation inhibitor and etoposide, and confirmed the proliferation patterns of the cancer cells using a colony formation assay. As a result, we confirmed that the proliferation of cancer cells was inhibited when the dnedylation inhibitor was administered. This implies that cancer cell proliferation can be effectively suppressed through a treatment method that combines a dnedylation inhibitor to reduce the amount of DDB1 protein within cells with a DNA-damaging agent.

[0122] In conclusion, it was confirmed that the reduction of DDB1 protein induced by denedylation inhibitors is a degradation phenomenon caused by self-ubiquitination by the CRL4 complex. Furthermore, a novel cancer treatment method was proposed through the effective inhibition of cancer cell growth achieved by simultaneously reducing DDB1 protein, which is crucial for DNA damage repair, using denedylation inhibitors and administering DNA damage-repairing drugs.

[0124] The present invention has been described above with reference to its preferred embodiments. Those skilled in the art will understand that the present invention may be embodied in modified forms without departing from the essential characteristics of the invention. Therefore, the disclosed embodiments should be considered in an illustrative rather than a restrictive sense. The scope of the invention is defined by the claims, not by the foregoing description, and all variations within the scope of the claims should be interpreted as being included in the invention.

Claims

Claim 1 A method for inducing self-ubiquitination of DDB1 protein, comprising the step of treating small cell lung cancer cell lines with CSN5i-3. Claim 2 delete Claim 3 A composition for enhancing the apoptotic sensitivity of small cell lung cancer to etoposide, comprising CSN5i-3 as an active ingredient. Claim 4 delete Claim 5 delete Claim 6 A pharmaceutical composition containing CSN5i-3 as an active ingredient, administered in combination with etoposide to support the therapeutic effect of small cell lung cancer. Claim 7 delete Claim 8 A pharmaceutical combination formulation for the prevention or treatment of small cell lung cancer, comprising CSN5i-3 and etoposide as active ingredients. Claim 9 delete Claim 10 A pharmaceutical combination formulation for the prevention or treatment of small cell lung cancer, characterized in that, in claim 8, the CSN5i-3 and etoposide can be administered simultaneously, separately, or sequentially. Claim 11 delete

Citation Information

Patent Citations

  • Method for identifying a chemical compound or agent inducing ubiquitination of a protein of interest

    US20210293788A1